Clinical Trials
3 trialsNCT02834247 2023-02-08
A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors
Calithera Biosciences, Inc
Phase 1 Terminated
NCT03238651 2023-02-08
A Study of TAK-659 as a Single Agent in Adult East Asian Participants With Non-Hodgkin Lymphoma (NHL)
Calithera Biosciences, Inc
Phase 1 Terminated
NCT02954406 2022-02-18
A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma
Takeda
Phase 1 Terminated